Fierce Biotech1 min read
saveAriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial. Fosun Pharma has an option to in-license the PDE5 inhibitor.
comments(0)
5-min edit window · permanent after that